$9M Direct Offering Closes for China SXT Pharmaceuticals via Univest — Univest Securities, LLC

Event summary

$9M registered direct offering closed for China SXT Pharmaceuticals (NASDAQ: SXTC) on July 24, 2026.
Offering included 4.5M units at $2.00 per unit, each consisting of one Class A ordinary share and one warrant.
Warrants exercisable immediately with a $3.20 exercise price, expiring one year from issuance.
Univest Securities acted as sole placement agent.

The big picture

This offering underscores the continued appetite for Chinese pharmaceutical companies to access U.S. capital markets despite regulatory scrutiny. Univest's role as sole placement agent highlights its niche in facilitating cross-border transactions, particularly in the life sciences sector. The deal size, while modest, reflects cautious investor sentiment toward emerging market healthcare firms.

What we're watching

Capital Deployment: How China SXT Pharmaceuticals will allocate the $9M proceeds to drive growth in traditional Chinese medicine.
Market Performance: Whether the immediate exercisable warrants will impact SXTC's stock volatility in the near term.
Execution Risk: The pace at which Univest can secure additional capital raises for similar clients in the life sciences sector.